Positive Phase 3 Topline Results for Early Parkinson's Drug
The novel drug P2B001 is superior to its individual components of pramipexole or rasagiline for early Parkinson's disease ― with less daytime sleepiness, new topline results suggest.
Medscape Medical News
source https://www.medscape.com/viewarticle/965583?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/965583?src=rss
Comments
Post a Comment